Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
>-AU$0.01(-5.56%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$11.48M
Enterprise ValueAU$5.17
Total Cash (Recent Filing)AU$8.09M
Total Debt (Recent Filing)AU$180.92K
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding637,981,000
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
Bulls Say, Bears Say
Bulls Say
Platform & Market PositionMedAdvisor operates a pharmacy-centric software platform plus a consumer medication app, creating network effects between pharmacies and patients. This entrenched market positioning supports recurring refill workflows and long-term engagement, underpinning durable revenue streams if adoption stabilises.
Free Cash Flow ImprovementPositive free cash flow growth and a FCF-to-net-income ratio of 1.0 indicate improving cash generation and alignment of cash performance with accounting results. Sustained FCF improvement enhances runway, reduces reliance on dilutive capital and supports operational turnaround over the medium term.
Operational Efficiency SignalA positive return on equity, even from a negative equity base, suggests the business can generate returns from limited equity capital. This hints at operational efficiency in core services which, if maintained, helps recovery efforts and provides a foundation for scaling revenue with restrained capital needs.
Bears Say
Steep Revenue DeclineA near 40% drop in revenue is a material structural weakness: it reduces scale, weakens pricing power, and makes fixed-cost absorption harder. Unless product-market fit or distribution is restored, sustained top-line contraction will impair margin recovery and long-term competitiveness.
Severely Negative ProfitabilityExtremely negative net and operating margins indicate the company is burning cash on core operations. Such deep unprofitability is unsustainable over time, forcing reliance on external capital, constraining investment in product and sales, and increasing execution risk for any turnaround plan.
Highly Stressed Balance SheetNegative shareholders' equity and an extreme debt-to-equity ratio signal solvency and financing stress. This materially limits financial flexibility, raises refinancing and covenant risk, and increases the likelihood of dilution or restructuring, all of which hamper mid-term strategic initiatives.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.01 and its highest was AU$0.08 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$11.48M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 35 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,981,000 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$20.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Oneview Healthcare Chess Depository Interests repr 1
―
PharmX Technologies
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―